Breast cancer screening tool predicts patient response to immunotherapies

California voters pass $8.4B bond for immunotherapy research

In this year’s midterm election, voters in California approved Proposition 38, a $8.4 billion bond to fund immunology and immunotherapy research.

Piktor regimen yields 33% confirmed ORR in advanced endometrial cancer, phase II study finds

Piktor, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel to patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR pathway mutation who had received at least one prior line of therapy, yielded a 33% confirmed objective response rate in efficacy-evaluable patients, and a disease control rate of 83%, according to clinical data from phase II trial (FTH-PIK-201; NCT06463028; GOG-311).

November 13, 2026

Vol.52 No.42

Clinical Roundup

Two “forever chemicals” are associated with higher risk of aggressive breast cancer, NIH analysis finds

Women with higher blood levels of two common per- and polyfluoroalkyl substances, also familiarly known as PFAS, were more likely to develop estrogen receptor-negative, or ER-negative, breast cancer, according to a study by NIH.

November 13, 2026

Vol.52 No.42

Cancer Policy

HHS announces initiative to improve breast cancer screening and early detection

HHS, through the recently announced Office of Women’s Health, announced taht it will be pursuing a collaboration with the Agency for Healthcare Research and Quality and DenseBreast-info.org to strengthen breast cancer screening, expand breast density education, and improve timely diagnostic follow-up, particularly for midlife women.

October 30, 2026

Vol.52 No.40

By Claire Marie Porter

In Brief

UIC receives $5.3 million NIH grant to study population genomic cancer screenings

Knowing your genetic risk for diseases like cancer can spur detection, prevention, and treatment. But some people don’t know or have access to their family’s medical history.

October 23, 2026

Vol.52 No.39

Clinical Roundup

Nutritional supplement may help ease brain fog after breast cancer treatment, UCLA study finds

A nutritional supplement containing oxaloacetate, a molecule naturally found in the body that helps cells produce energy, may help improve cognitive function and reduce the fatigue experienced by some breast cancer survivors following treatment, according to a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center.

October 23, 2026

Vol.52 No.39

Breast cancer screening tool predicts patient response to immunotherapies

YOU MAY BE INTERESTED IN

California voters pass $8.4B bond for immunotherapy research

Piktor regimen yields 33% confirmed ORR in advanced endometrial cancer, phase II study finds

Two “forever chemicals” are associated with higher risk of aggressive breast cancer, NIH analysis finds

HHS announces initiative to improve breast cancer screening and early detection

UIC receives $5.3 million NIH grant to study population genomic cancer screenings

Nutritional supplement may help ease brain fog after breast cancer treatment, UCLA study finds

Renew today!

Subscriber content

Never miss an issue!

Login